Claims for Patent: 10,799,497

Summary for Patent: 10,799,497

Title:	Combination of dextromethorphan and bupropion for treating depression
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US16/736,752
Patent Claims:	1. A method of treating major depressive disorder, comprising: orally administering a dosage form once a day or twice a day for at least 23 days, to a human being suffering from major depressive disorder, wherein the dosage form contains, as the only therapeutically active compounds in the dosage form, about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan, and about 90 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and wherein the dosage form provides immediate release of dextromethorphan and sustained release of bupropion. 2. The method of claim 1, wherein the dosage form contains about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan and is orally administered twice a day. 3. The method of claim 1, wherein the dosage form contains about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion and is orally administered twice a day. 4. The method of claim 1, wherein the dosage form contains about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion and is orally administered twice a day. 5. The method of claim 1, wherein the dosage form is orally administered for at least 35 days. 6. The method of claim 1, wherein the human being is suffering from treatment-resistant depression. 7. The method of claim 1, wherein the dosage form is orally administered twice a day. 8. The method of claim 7, wherein the dosage form is orally administered for at least 5 weeks. 9. The method of claim 1, wherein dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan, comprises a deuterium-modified dextromethorphan. 10. A method of treating treatment-resistant depression comprising: orally administering a dosage form once a day or twice a day for at least about 30 days to a human being suffering from treatment-resistant depression; wherein the dosage form comprises, as the only therapeutically active compounds in the dosage form, about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan, and about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and wherein the dosage form provides immediate release of dextromethorphan and sustained release of bupropion. 11. The method of claim 10, wherein dextromethorphan hydrobromide, or the free base form or another salt form of dextromethorphan, comprises a deuterium-modified dextromethorphan. 12. The method of claim 10, wherein the dosage form comprises about 100 mg to about 110 mg of bupropion hydrochloride. 13. The method of claim 10, wherein the dosage form comprises about 45 mg of dextromethorphan hydrobromide. 14. The method of claim 13, wherein the dosage form comprises about 105 mg of bupropion hydrochloride.